RedHill Biopharma Ltd. (RDHL)
USD 2.43
(-12.77%)
USD 2.43
(-12.77%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 23.04 Million USD | -85.49% |
| 2022 | 158.87 Million USD | -12.32% |
| 2021 | 181.18 Million USD | 0.53% |
| 2020 | 180.24 Million USD | 143.24% |
| 2019 | 74.09 Million USD | 18.73% |
| 2018 | 62.41 Million USD | 8.84% |
| 2017 | 57.34 Million USD | -22.73% |
| 2016 | 74.21 Million USD | 11.05% |
| 2015 | 66.82 Million USD | 131.59% |
| 2014 | 28.85 Million USD | 101.23% |
| 2013 | 14.34 Million USD | -28.64% |
| 2012 | 20.09 Million USD | -0.45% |
| 2011 | 20.18 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 FY | 23.04 Million USD | -85.49% |
| 2023 Q2 | 35.03 Million USD | -40.45% |
| 2023 Q1 | 58.83 Million USD | -62.97% |
| 2022 Q1 | 167.04 Million USD | -7.8% |
| 2022 FY | 158.87 Million USD | -12.32% |
| 2022 Q4 | 158.87 Million USD | 1.07% |
| 2022 Q3 | 157.19 Million USD | -6.41% |
| 2022 Q2 | 167.96 Million USD | 0.55% |
| 2021 Q1 | 220.12 Million USD | 22.13% |
| 2021 Q4 | 181.18 Million USD | -2.76% |
| 2021 Q3 | 186.33 Million USD | -8.51% |
| 2021 FY | 181.18 Million USD | 0.53% |
| 2021 Q2 | 203.67 Million USD | -7.47% |
| 2020 Q3 | 168.98 Million USD | 1.57% |
| 2020 Q4 | 180.24 Million USD | 6.66% |
| 2020 Q1 | 143.48 Million USD | 93.63% |
| 2020 FY | 180.24 Million USD | 143.24% |
| 2020 Q2 | 166.37 Million USD | 15.95% |
| 2019 Q2 | 49.69 Million USD | -14.52% |
| 2019 Q3 | 40.24 Million USD | -19.02% |
| 2019 Q4 | 74.09 Million USD | 84.12% |
| 2019 FY | 74.09 Million USD | 18.73% |
| 2019 Q1 | 58.13 Million USD | -6.85% |
| 2018 FY | 62.41 Million USD | 8.84% |
| 2018 Q4 | 62.41 Million USD | 16.93% |
| 2018 Q3 | 53.37 Million USD | 41.03% |
| 2018 Q2 | 37.84 Million USD | -18.42% |
| 2018 Q1 | 46.39 Million USD | -19.09% |
| 2017 Q1 | 69.6 Million USD | -6.21% |
| 2017 FY | 57.34 Million USD | -22.73% |
| 2017 Q4 | 57.34 Million USD | 14.0% |
| 2017 Q3 | 50.29 Million USD | -18.85% |
| 2017 Q2 | 61.98 Million USD | -10.95% |
| 2016 Q1 | 61.55 Million USD | -7.89% |
| 2016 FY | 74.21 Million USD | 11.05% |
| 2016 Q4 | 74.21 Million USD | 51.82% |
| 2016 Q3 | 48.88 Million USD | -13.11% |
| 2016 Q2 | 56.25 Million USD | -8.61% |
| 2015 FY | 66.82 Million USD | 131.59% |
| 2015 Q4 | 66.82 Million USD | -6.85% |
| 2015 Q3 | 71.74 Million USD | 108.67% |
| 2015 Q2 | 34.38 Million USD | -16.61% |
| 2015 Q1 | 41.22 Million USD | 42.88% |
| 2014 Q1 | 40.58 Million USD | 183.01% |
| 2014 FY | 28.85 Million USD | 101.23% |
| 2014 Q4 | 28.85 Million USD | -15.84% |
| 2014 Q3 | 34.28 Million USD | -12.63% |
| 2014 Q2 | 39.24 Million USD | -3.29% |
| 2013 Q4 | 14.34 Million USD | -11.56% |
| 2013 FY | 14.34 Million USD | -28.64% |
| 2013 Q2 | 17.01 Million USD | -8.97% |
| 2013 Q1 | 18.69 Million USD | -6.98% |
| 2013 Q3 | 16.21 Million USD | -4.71% |
| 2012 FY | 20.09 Million USD | -0.45% |
| 2012 Q3 | 15.3 Million USD | 0.0% |
| 2012 Q4 | 20.09 Million USD | 31.27% |
| 2011 Q4 | 20.18 Million USD | 0.0% |
| 2011 FY | 20.18 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Bright Green Corporation | 17.4 Million USD | -32.432% |
| Alpha Teknova, Inc. | 128.58 Million USD | 82.077% |
| ANI Pharmaceuticals, Inc. | 904.42 Million USD | 97.452% |
| Aquestive Therapeutics, Inc. | 57.41 Million USD | 59.861% |
| Collegium Pharmaceutical, Inc. | 1.14 Billion USD | 97.984% |
| Cosmos Health Inc. | 66.29 Million USD | 65.236% |
| Journey Medical Corporation | 76.84 Million USD | 70.01% |
| Embecta Corp. | 1.21 Billion USD | 98.102% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | 88.801% |
| Dynavax Technologies Corporation | 997.09 Million USD | 97.689% |
| Intra-Cellular Therapies, Inc. | 728.29 Million USD | 96.835% |
| Pacira BioSciences, Inc. | 1.57 Billion USD | 98.536% |
| PainReform Ltd. | 9.93 Million USD | -132.096% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | 15.723% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | 15.723% |
| SCYNEXIS, Inc. | 128.41 Million USD | 82.052% |
| Safety Shot Inc | 12.7 Million USD | -81.342% |
| China SXT Pharmaceuticals, Inc. | 23.12 Million USD | 0.346% |
| Procaps Group, S.A. | 460.18 Million USD | 94.992% |
| Theratechnologies Inc. | 77.76 Million USD | 70.365% |
| Harrow Health, Inc. | 311.75 Million USD | 92.607% |
| Sonoma Pharmaceuticals, Inc. | 14.89 Million USD | -54.751% |
| Biofrontera Inc. | 27.93 Million USD | 17.488% |
| DURECT Corporation | 45.18 Million USD | 48.998% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 98.364% |
| Cronos Group Inc. | 1.13 Billion USD | 97.968% |
| OptiNose, Inc. | 107.72 Million USD | 78.606% |
| Ironwood Pharmaceuticals, Inc. | 471.07 Million USD | 95.108% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | 58.807% |
| Organogenesis Holdings Inc. | 460.02 Million USD | 94.99% |
| Guardion Health Sciences, Inc. | 11.91 Million USD | -93.378% |
| Cumberland Pharmaceuticals Inc. | 81.77 Million USD | 71.817% |
| Radius Health, Inc. | 1.71 Billion USD | 98.657% |
| Universe Pharmaceuticals INC | 53.28 Million USD | 56.749% |
| ProPhase Labs, Inc. | 91.92 Million USD | 74.929% |
| Phibro Animal Health Corporation | 982.18 Million USD | 97.653% |
| Procaps Group S.A. | 460.18 Million USD | 94.992% |
| Alvotech | 950.09 Million USD | 97.574% |
| TherapeuticsMD, Inc. | 43.3 Million USD | 46.784% |
| Viatris Inc. | 47.68 Billion USD | 99.952% |
| Rockwell Medical, Inc. | 52.17 Million USD | 55.826% |
| Aytu BioPharma, Inc. | 118.09 Million USD | 80.484% |
| SIGA Technologies, Inc. | 254.83 Million USD | 90.956% |
| Tilray Brands, Inc. | 4.33 Billion USD | 99.468% |
| Lifecore Biomedical, Inc. | 273.7 Million USD | 91.579% |
| Shineco, Inc. | 84.17 Million USD | 72.621% |
| PetIQ, Inc. | 868.22 Million USD | 97.345% |
| Regencell Bioscience Holdings Limited | 8.43 Million USD | -173.128% |
| Incannex Healthcare Limited | 17.04 Million USD | -35.198% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 99.291% |
| Alimera Sciences, Inc. | 153.52 Million USD | 84.988% |
| Silver Spike Investment Corp. | 88.57 Million USD | 73.98% |
| Assertio Holdings, Inc. | 286.41 Million USD | 91.953% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.95 Million USD | -287.234% |
| Petros Pharmaceuticals, Inc. | 33.79 Million USD | 31.805% |
| Clever Leaves Holdings Inc. | 31.24 Million USD | 26.233% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -73.973% |
| Avadel Pharmaceuticals plc | 261.12 Million USD | 91.174% |
| Hempacco Co., Inc. | 18.04 Million USD | -27.734% |
| Talphera, Inc. | 20.39 Million USD | -13.004% |
| Alvotech | 950.09 Million USD | 97.574% |
| Eagle Pharmaceuticals, Inc. | 406.16 Million USD | 94.326% |
| Lantheus Holdings, Inc. | 1.65 Billion USD | 98.604% |
| Currenc Group, Inc. | 141.49 Million USD | 83.711% |
| Kamada Ltd. | 351.96 Million USD | 93.452% |
| Indivior PLC | 1.95 Billion USD | 98.819% |
| Evoke Pharma, Inc. | 7.06 Million USD | -226.052% |
| Flora Growth Corp. | 23.62 Million USD | 2.45% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -73.973% |
| Evolus, Inc. | 188.99 Million USD | 87.806% |
| HUTCHMED (China) Limited | 1.27 Billion USD | 98.199% |
| Amphastar Pharmaceuticals, Inc. | 1.51 Billion USD | 98.477% |
| Akanda Corp. | 8.83 Million USD | -160.714% |